How do you treat at the speed of cancer?

The Answers AreIn Our Blood

Guardant360® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors

left hand right hand

Get essential
answers before
choosing treatment.

Learn how liquid biopsy has
changed the treatment paradigm.
FDA Approved FDA Approved

Draw blood first; make plans fast with FDA-approved Guardant360 CDx.

Get guideline-complete genomic results in only 7 days with a simple blood draw.

Seamlessly integrate
Guardant360 CDx
into your practice.

Comprehensive support and educational
resources for you and your patients.
Medical-Care-Team_2_fin_cmyHR Medical-Care-Team_2_fin_cmyHR
Latest clinical data.*
View the evidence
New England Journal Of Medicine
Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Clinical Cancer Research
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer.
JAMA Oncology
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Clinical Lung Cancer
Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Journal of Clinical Oncology
Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis.

*Disclaimer: This content has not been reviewed by the FDA. Data shown for the performance of Guardant360® Laboratory Developed Test (LDT) does not convey the performance of Guardant360 CDx.